Fund moves
97KShares reported
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BLFS · NASDAQ · Health Care Supplies
No longer listed: the shares stopped trading on Oct 7, 2026, usually after a takeover, a merger or a move off the exchange. The price and the charts stop there; the filings stay.
BioLife Solutions, Inc. (BLFS) · oqro.io/stocks/BLFS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
$38.61+1.31 (+3.51%)
Close of Oct 5, 2026, vs Oct 2 · end-of-day
No open-market purchase by an insider of BioLife Solutions, Inc. was filed in the last 90 days. The latest on record was on Oct 19, 2023.
Since 2005, BioLife Solutions, Inc. insiders reported 40 open-market purchases and 917 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2023.
+41.3% (+$11.29) from Oct 17, 2025 to Oct 5, 2026 · adjusted daily closes
Adjusted close went from $27.32 on Oct 17, 2025 to $38.61 on Oct 5, 2026 (+41.3%). Disclosed in this range: 15 insider trades, 27 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 1 quarter ending in it.
No open-market sale by an insider of BioLife Solutions, Inc. (BLFS) was filed with the SEC in the last 90 days.
No trade in BioLife Solutions, Inc. (BLFS) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Supplies company based in Bothell, Washington.
Last 12 months
Not enough history
Market value
$1.89B
Short interest: 4M shares sold short (8.2% of shares outstanding), +3.0% vs the previous count, 4.3 days of normal trading to buy them back. FINRA, as of Sep 30, 2026. Short interest history
Revenue, fiscal 2025
$96.2M
+28.9% vs the year before
Net income, fiscal 2025
−$4.59M
A loss for the year
Shares outstanding
48.9M
As of Jul 30, 2026
New federal contracts from the last 12 months add up to 0.05% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Federal contracts
26-007655 cryostor CS10, 100 ml bags for cell therapy manufacturing
The Department of Health and Human Services has committed $45K to BioLife Solutions so far. It runs until Sep 18, 2026.
Insider selling
Traded May 21 · filed the same dayNot reported under a pre-arranged trading plan
A major shareholder of BioLife Solutions sold $15.4M of BioLife Solutions shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Oct 2, 2025, BLFS is up 49.0% and the index fund is up 15.8%: 33 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BLFS moves
Beta 1.1 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 217 trading days (1 = in step with it).
Insiders of BioLife Solutions, Inc. reported 40 open-market purchases and 917 sales since 2005; purchases in 6 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $30.2M17×17 trades |
| 2025 | — | $76.4M102×102 trades |
| 2024 | — | $5.81M98×98 trades |
| 2023 | $14.4M7×7 trades | $6.24M122×122 trades |
| 2022 | — | $9.2M114×114 trades |
| 2021 | — | $60.6M193×193 trades |
| 2020 | $75.4M5×5 trades | $114M114×114 trades |
| 2019 | $617K2×2 trades | $18.4M122×122 trades |
| 2018 | — | $14.7M35×35 trades |
| 2014 | $1.36M22×22 trades | — |
| 2006 | $93K2×2 trades | — |
| 2005 | $495K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Notice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
BlackRock, Inc.
13G · passive · Amended · 6.58M shares · filed Oct 27, 2026
Glazer Capital, LLC
13G · passive · Amended · 4.08M shares · filed Nov 16, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Deals
Things to keep in mind
Records
Revenue
$28.5M
+21.5% vs the same quarter a year earlier
Free cash flow, last 12 months
$5.3M
This quarter $5.3M, a year earlier $5.63M
Net cash
$24M
Debt $0, cash $24M, at Jun 30, 2026
Net income, last 12 months
$58M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Revenue and earnings history, 16 fiscal yearsEarnings dates and the stock's moves
Off-exchange trading: 43.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (25.0% on ATS, 18.3% with other brokers), close to its 24-week average of 42.1%. Weeks of Sep 14 to Oct 9, 2026.
Largest ATS: ONECHRONOS (18.4%), UBS ATS (17.3%), SIGMA X2 (11.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution. a discontinued operation for all periods presented. See Note 3: Discontinued operations within the Consolidated Financial Statements in Part II, Item 8 of this Annual Report for further details regarding the divestiture.
And 24 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Feb 26, 2026, compared with the one filed Mar 3, 2025. Read the filing
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.